Brief: Positive Results From Interim Analysis Of 'GEN-001' Plus Avelumab Phase II Trial

Genome&Company

19/05/2023 14:45

May 19 (Reuters) - Genome&Company  314130.KQ :
    * POSITIVE RESULTS FROM INTERIM ANALYSIS OF 'GEN-001' PLUS
AVELUMAB (BAVENCIO®) PHASE II TRIAL
    * GENOME&COMPANY - TOP-LINE DATA OF FINAL ANALYSIS FROM
PHASE II
TO BE ANNOUNCED IN SECOND HALF OF NEXT YEAR

Source text for Eikon:  ID:nPn2mYvTPa 
Further company coverage:  314130.KQ 

 ((Reuters.Brief@thomsonreuters.com;))